Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?

Thermo Fisher Scientific Inc. (NYSE: TMO ) and Danaher Corporation (NYSE: DHR ) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE: TMO ) raised guidance on broad-based demand improvement, Danaher's (NYSE: DHR ) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?

Thermo Fisher Scientific Inc. (NYSE: TMO ) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. Danaher Corporation's (NYSE: DHR ) second-quarter results, on the other hand, were marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth.

Thermo Fisher Scientific Inc.'s (NYSE: TMO ) quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Management highlighted improving customer activity across pharmaceutical and biotechnology markets, while multiple operating segments returned to healthy growth. That is encouraging because recoveries driven by several business lines tend to be more durable than those supported by a single segment.

Thermo Fisher Scientific Inc.'s (NYSE: TMO ) Life Sciences Solutions segment reinforced the recovery narrative. Reported revenue climbed 13% year over year, while organic revenue rose 3%, led by continued strength in the high-margin bioproduction business. Healthy demand in this segment is particularly encouraging because it reflects ongoing investments and supports management's view that end-market conditions continue to improve.

Perhaps the biggest positive from the quarter was the recovery in Analytical Instruments, a business that had faced weak demand for nearly two years as biotechnology funding slowed. Its return to growth provides another indication that laboratory spending is beginning to normalize. While one quarter does not establish a trend, sustained improvement in this segment would strengthen the case that the industry's post-pandemic downturn is easing.

Thermo Fisher Scientific Inc. (NYSE: TMO ) also continued investing in product innovation through launches such as the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers. Continued innovation has historically helped the company defend its competitive position in premium analytical instruments, which could become increasingly important as customer spending gradually improves.

Danaher Corporation's (NYSE: DHR ) results also pointed to improving fundamentals, although the recovery appears less mature than Thermo Fisher's (NYSE: TMO ). The company's Life Sciences business delivered its strongest performance in several years, while bioprocessing orders increased at a mid-teens rate despite reported revenue being affected by customer project timing. Strong orders matter because they often precede future revenue recognition, suggesting underlying customer demand may be healthier than current reported sales imply.

Management also disclosed that just over $100 million of revenue shifted into next year because of customer project timing. If those projects proceed as expected, that revenue has been deferred rather than lost, potentially providing an additional tailwind in future quarters. Danaher Corporation (NYSE: DHR ) further noted that academic and government markets have largely stabilized. Although it stopped short of describing those markets as fully recovered, stabilization removes one of the major headwinds that weighed on life sciences spending over the past two years.